



Published in final edited form as:

*Immunity*. 2015 December 15; 43(6): 1112–1124. doi:10.1016/j.immuni.2015.11.005.

## The inhibitory receptor NKG2A sustains virus-specific CD8<sup>+</sup> T cells in response to a lethal poxvirus infection

Aaron S. Rapaport<sup>1</sup>, Jill Schriewer<sup>2</sup>, Susan Gilfillan<sup>1</sup>, Ed Hembrador<sup>2</sup>, Ryan Crump<sup>2</sup>, Beatrice F. Plougastel<sup>3</sup>, Yaming Wang<sup>1</sup>, Gaelle Le Fric<sup>1,6</sup>, Jian Gao<sup>3</sup>, Marina Cella<sup>1</sup>, Hanspeter Pircher<sup>4</sup>, Wayne M. Yokoyama<sup>3,5</sup>, R. Mark L. Buller<sup>2</sup>, and Marco Colonna<sup>1,#</sup>

<sup>1</sup>Department of Pathology and Immunology, Washington University School of Medicine, 660 S. Euclid, St Louis, MO 63110, USA

<sup>2</sup>Department of Molecular Microbiology and Immunology, Saint Louis University Health Sciences Center, 1402 South Grand Blvd, St Louis, MO 63104, USA

<sup>3</sup>Rheumatology Division, Department of Medicine, Washington University School of Medicine, 660 S. Euclid, St Louis, MO 63110, USA

<sup>4</sup>Institute of Immunology, Center for Microbiology and Hygiene, University Medical Center Freiburg, Hermann-Herder Strasse 11, D-79104 Freiburg, Germany

<sup>5</sup>Howard Hughes Medical Institute, Washington University School of Medicine, 660 S. Euclid, St Louis, MO 63110, USA

### Summary

CD8<sup>+</sup> T cells and NK cells protect from viral infections by killing virally-infected cells and secreting interferon- $\gamma$ . Several inhibitory receptors limit the magnitude and duration of these anti-viral responses. NKG2A, which is encoded by *Klrc1*, is a lectin-like inhibitory receptor that is expressed as a heterodimer with CD94 on NK cells and activated CD8<sup>+</sup> T cells. Previous studies on the impact of CD94/NKG2A heterodimers on anti-viral responses have yielded contrasting results and the *in vivo* function of NKG2A remains unclear. Here, we generated *Klrc1*<sup>-/-</sup> mice and found that NKG2A is selectively required for resistance to ectromelia virus (ECTV). NKG2A functions intrinsically within ECTV-specific CD8<sup>+</sup> T cells to limit excessive activation, prevent apoptosis, and preserve the specific CD8<sup>+</sup> T cell response. Thus, while inhibitory receptors often cause T cell exhaustion and viral spreading during chronic viral infections, NKG2A optimizes CD8<sup>+</sup> T cell responses during an acute poxvirus infection.

### Keywords

Virus; cytokine; CD8<sup>+</sup> T cell; NK cell; inhibitory receptor; NKG2A

<sup>#</sup>corresponding author: mcolonna@pathology.wustl.edu.

<sup>6</sup>Present address: Division of Transplant Immunology and Mucosal Biology, MRC Centre for Transplantation, King's College London, Guy's Hospital, Great Maze Pond, London SE1 9RT, UK

**Publisher's Disclaimer:** This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Introduction

CD8<sup>+</sup> T cells and NK cells contribute to host defense against viral infections by killing virally infected cells and secreting interferon- $\gamma$  (IFN- $\gamma$ ) (Biron, 2010). Both CD8<sup>+</sup> T cells and NK cells are equipped with multiple inhibitory receptors that control the magnitude and duration of cytotoxic lymphocyte responses (Odorizzi and Wherry, 2012). These receptors can instigate disparate impacts on anti-viral responses. When cognate ligands are expressed on infected cells, inhibitory receptors control the release of lytic mediators and IFN- $\gamma$ . This process may reduce tissue damage and immunopathology during acute infections (Frebel et al., 2012; Rygiel et al., 2009), but may facilitate T cell exhaustion and viral replication during chronic viral infections (Odorizzi and Wherry, 2012). Some viruses encode ligands that engage NK cell and CD8<sup>+</sup> T cell inhibitory receptors to impede killing of virally infected cells and facilitate viral replication (Lanier, 2008). When cognate ligands are expressed on dendritic cells (DC) or T cells, inhibitory receptors may prevent NK cell-mediated lysis of DC or T cells that participate in the adaptive immune response (Lu et al., 2007; Waggoner et al., 2012; Waggoner et al., 2010; Xu et al., 2014). In this case, inhibitory receptors may accelerate the clearance of virally infected cells but also promote excessive adaptive responses, causing tissue damage and immunopathology.

NKG2A is an inhibitory receptor expressed on a subset of NK cells and activated CD8<sup>+</sup> T cells. It belongs to a family of lectin-like cell receptors that comprise three distinct isoforms, NKG2A (encoded by the *Klrc1* gene), NKG2C (encoded by the *Klrc2* gene), and NKG2E (encoded by the *Klrc3* gene), collectively called NKG2X. NKG2A pairs with CD94 (encoded by the *Klrkl* gene) to form a heterodimer that binds the non-classical class I molecule Qa-1 in mice (Vance et al., 1998; Zeng et al., 2012) and human leukocyte antigen E (HLA-E) in humans (Braud et al., 1998; Lee et al., 1998; Sullivan et al., 2007). The dominant peptide bound to Qa-1, named Qdm, is derived from the leader sequences of mouse major histocompatibility complex (MHC) class I molecules H-2D and H-2L (Aldrich et al., 1994; Zeng et al., 2012). NKG2A transmits intracellular inhibitory signals by recruiting the protein tyrosine phosphatases SHP1 and SHP2 (Kabat et al., 2002; Le Dren et al., 1998). NKG2C and NKG2E also pair with CD94 to bind Qa-1 (Vance et al., 1999). However, NKG2C and NKG2E transmit activating signals through the transmembrane adapter DAP12, which recruits the protein tyrosine kinases Syk and ZAP70 (Taylor et al., 2000). While NKG2C and NKG2E directly bind DAP12 through a salt bridge in their transmembrane domains in humans (Call et al., 2010), NKG2C and NKG2E associate with DAP12 indirectly in mice, because murine CD94 forms a salt bridge with DAP12 in its transmembrane region (Saether et al., 2011).

Previous investigations of CD94/NKG2A heterodimer function during viral infections using blocking antibodies or Qa-1-deficient mice have yielded contrasting results. CD94/NKG2A heterodimers inhibited CD8<sup>+</sup> T cell cytotoxic responses to polyoma virus (Moser et al., 2002) and inhibited NK-cell mediated killing of cells infected with human cytomegalovirus (HCMV) (Tomasec et al., 2000). In contrast, CD94/NKG2A heterodimers did not inhibit CD8<sup>+</sup> T cell effector functions during lymphocytic choriomeningitis virus (LCMV) or listeria monocytogenes (LM) infections (McMahon et al., 2002; Miller et al., 2002). Another

report suggested that CD94/NKG2X complexes may protect both NK and T cells from apoptosis during LM infection (Gunturi et al., 2003). More recently, it was shown that CD94-deficient (*Klrcl1*<sup>-/-</sup>) mice are highly susceptible to mouse orthopoxvirus ectromelia virus (ECTV) infection (Fang et al., 2011). However, susceptibility to infection was not attributed to lack of CD94/NKG2A heterodimers, but rather to loss of the activating CD94/NKG2E/DAP12 complex, which possibly triggered lysis of ECTV-infected cells through recognition of a viral peptide bound to Qa-1. Finally, *Klrcl1*<sup>-/-</sup> mice had more immunopathology during influenza and adenovirus infections (Ely et al., 2014)

To unequivocally determine the function of NKG2A during viral infections *in vivo* we generated *Klrcl1*<sup>-/-</sup> mice on the C56BL/6 background and tested immune responses against LCMV, VSV, Vaccinia Virus (VV) and ECTV. We found that *Klrcl1*<sup>-/-</sup> mice are uniquely susceptible to infection by ECTV and that NKG2A is required to sustain virus-specific CD8<sup>+</sup> T cells by preventing activation-induced cell death (AICD).

## Results

### Mouse NK cells lack surface expression of NKG2C and NKG2E

To generate *Klrcl1*<sup>-/-</sup> mice we targeted exons 1 through 4 of *Klrcl1* (Figure S1A). We confirmed that mouse splenocytes lack *Klrcl1* transcripts, but maintain transcription of *Klrc2* and *Klrc3* (Figure S1B), indicating that the deletion is limited to the *Klrcl1* gene. NK, NKT and T cells from spleens, livers and lungs were present at similar frequencies in *Klrcl1*<sup>-/-</sup> and WT control mice (Figure S1C). NK cells from *Klrcl1*<sup>-/-</sup> mice were mature, as judged by CD11b and CD27 expression. Thus, NKG2A plays no obvious role in the development of NK or T cells. Splenic NK cells also showed normal expression of KLRG1, CD49b, Ly49 family members and NKG2D (Figure S1D), indicating that the receptor repertoire is undisturbed by the NKG2A deletion. These results are consistent with previous studies on DBA/2J mice, which are naturally deficient for CD94, yet exhibit no developmental defects (Vance et al., 2002).

To verify that NKG2A expression was completely ablated in *Klrcl1*<sup>-/-</sup> mice, we assessed cell surface expression by flow cytometry using an antibody that recognizes all three mouse NKG2X family members. Approximately 40% of WT splenic NK cells expressed NKG2X on the surface under steady state conditions. Notably, NK cells from *Klrcl1*<sup>-/-</sup> spleens completely lacked NKG2X surface expression (Figure 1A), suggesting that NKG2A is the only NKG2X family member expressed on the surface of mouse NK cells. Because NKG2E has been implicated in the control of ECTV (Fang et al., 2011), we monitored NKG2X expression on NK cells after ECTV infection. However, NK cells from *Klrcl1*<sup>-/-</sup> spleens completely lacked NKG2X surface expression even after infection. We next assessed NKG2X expression on T cells. Only a small population of naïve WT CD8<sup>+</sup> T cells was positive for NKG2X expression. CD8<sup>+</sup> T cells from *Klrcl1*<sup>-/-</sup> spleens also expressed little to no NKG2X under homeostatic conditions. After infection with ECTV, approximately one-quarter of WT CD8<sup>+</sup> T cells were NKG2X<sup>+</sup>, whereas only 0.4% of *Klrcl1*<sup>-/-</sup> CD8<sup>+</sup> T cells were NKG2X<sup>+</sup> (Figure 1B). We corroborated these observations by staining NK cells and activated CD8<sup>+</sup> T cells with both anti-NKG2ACE and an antibody specific for NKG2A<sup>B6</sup> only. Both antibodies stained each WT population equivalently and did not mark any cells

from *Klrc1*<sup>-/-</sup> samples (Figure S1E). These data are in agreement with previous studies showing that NKG2A comprises almost all of the NKG2X molecules found on mouse NK cells and activated CD8<sup>+</sup> T cells (Kawamura et al., 2009; Vance et al., 2002)

### CD94 is surface expressed with DAP12 in the absence of NKG2X

Analysis of CD94 expression confirmed lack of detectable NKG2C or NKG2E associated with CD94. WT NK cells from uninfected and ECTV-infected mice showed two peaks of CD94 expression; the higher peak corresponded to CD94/NKG2X complexes, while the lower peak lacked NKG2X (Figure 1C top panel, and 1A). The CD94<sup>hi</sup> peak was undetectable on *Klrc1*<sup>-/-</sup> NK cells, indicating that NK cells express CD94/NKG2X complexes exclusively in the form of CD94/NKG2A heterodimers. CD8<sup>+</sup> T cells in both WT and *Klrc1*<sup>-/-</sup> mice expressed similar amounts of CD94 after ECTV infection. However, *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cells expressed CD94 overwhelmingly without NKG2X proteins (Figure 1C bottom panel, and Figure 1B). Our CD94 expression analysis therefore demonstrates that although mouse CD94 preferentially associates with NKG2A, it is expressed in lower amounts (CD94<sup>low</sup>) in the absence of NKG2A. Coupled with the lack of NKG2C and NKG2E expression in the mouse, this indicates that CD94 may also function as part of a yet-to-be-characterized receptor complex.

A recent study has shown that mouse CD94 contains a charged transmembrane residue capable of associating directly with the adaptors DAP10 and DAP12 (Saether et al., 2011). We therefore sought to test whether CD94<sup>low</sup>NKG2X<sup>-</sup> NK cells required DAP10 (encoded by the *Hcst* gene) or DAP12 (encoded by the *Tyrobp* gene) for surface expression of CD94. We found that the CD94<sup>low</sup> population was markedly reduced in *Tyrobp*<sup>-/-</sup> NK cells, whereas it was maintained in *Hcst*<sup>-/-</sup> NK cells (Figure 1D). For controls, we confirmed that Ly49H expression was largely ablated in *Tyrobp*<sup>-/-</sup> NK cells and that NKG2X expression was maintained (Figure 1E). This indicates that in mouse NK cells, CD94 itself may function as a DAP12-associated activating NK receptor. Since activated CD8<sup>+</sup> T cells express DAP10 but not DAP12, we also asked whether CD94/NKG2A heterodimers require DAP10 for surface expression. As expected, we found that expression of this heterodimer was maintained on *Hcst*<sup>-/-</sup> nonspecific and antigen-specific CD8<sup>+</sup> T cells (Figure 1F). It is likely that in the absence of NKG2A, CD94 surface expression requires DAP10, although a formal demonstration requires the generation of *Klrc1*<sup>-/-</sup> × *Hcst*<sup>-/-</sup> mice. Taken together, this data indicates that two CD94 complexes are found on the surface of mouse killer cells: one containing NKG2A and another that lacks a *Klrc*-encoded partner (Figure 1G).

### NKG2A is important for the control of ECTV infection

Since a previous study indicated that an intact CD94-dependent NK cell response is required to resist infection to ECTV (Fang et al., 2011) and we were unable to detect expression of either NKG2C or NKG2E on NK cells, we hypothesized that NKG2A may play an important role in controlling this infection. Therefore, we challenged *Klrc1*<sup>-/-</sup> mice with a standard 1000 PFU dose of ECTV in the footpad and observed that *Klrc1*<sup>-/-</sup> male mice were very susceptible to this infection, evident by increased morbidity and mortality (Figures 2A and 2B) as well as elevated viremia and splenic viral loads 6-10 days post-infection (Figures 2C). *Klrc1*<sup>-/-</sup> female mice also had higher viremia and splenic viral loads

than did WT female mice, although morbidity and mortality were similar. It has been shown that males are more vulnerable than females in mouse strains susceptible to ECTV (Brownstein and Gras, 1995). Here, we also noted that males, in general, had higher viremia and liver titers than their female counterparts (Figures 2C). Thus, the severe susceptibility of the *Klrc1*<sup>-/-</sup> males appears to be a combination of a general male vulnerability to ECTV coupled with a *bona fide* role for NKG2A in the anti-ECTV response.

We next assessed the blood for any disruptions in cellularity. At 7 days post-infection, we noted significant increases in total white blood cell (WBC) counts, specifically in the number of neutrophils and lymphocytes, concomitant with a corresponding reduction in the number of platelets per volume of blood in *Klrc1*<sup>-/-</sup> mice (Figure 2D). Marked histopathology was also evident in hematoxylin and eosin (H&E) staining of spleen sections from *Klrc1*<sup>-/-</sup> mice, which were highly acellular with disrupted tissue architecture compared to WT controls 7 days post-infection (Figures 2E and 2F). The acellularity of *Klrc1*<sup>-/-</sup> spleens was attributable to reduction in multiple leukocyte populations, including NK cells, T cells, B cells, dendritic cells, and macrophages (Figure 2G). Neutrophil and monocyte frequencies, however, were relatively increased and numbers were largely maintained in *Klrc1*<sup>-/-</sup> spleens, indicating that any perturbation due to the anti-viral response also resulted in accrual of neutrophils and monocytes (Figure 2H). In contrast, livers, lungs, and kidneys from *Klrc1*<sup>-/-</sup> mice appeared to remain largely intact and comparable to WT tissues after ECTV infection (data not shown). Therefore, ECTV infection causes pathology preferentially in the spleen and blood of *Klrc1*<sup>-/-</sup> mice.

### ***Klrc1*<sup>-/-</sup> mice harbor an otherwise intact *Klrc* locus and susceptibility to ECTV segregates with the targeted mutation of *Klrc1***

We wanted to ensure that these results were wholly attributable to elimination of NKG2A expression and not to more drastic disruption of the *Klrc* locus, possibly engendered during targeting. Therefore we sequenced the entire *Klrc* locus to confirm that it remained intact (apart from the targeted deletion of *Klrc1*) in the *Klrc1*<sup>-/-</sup> mice. The only mutations found within the *Klrc1*<sup>-/-</sup> line were an approximately 2.5kb deletion corresponding to the targeted deletion of *Klrc1* and few surrounding point mutations that were likely introduced during PCR amplification of the homology arms of the targeting construct (Table S1). Furthermore, as mentioned previously, *Klrc2* and *Klrc3* transcripts were present at similar levels in the spleens of both WT and *Klrc1*<sup>-/-</sup> mice (Figure S1B), indicating that the deletion and point mutations did not disrupt transcriptional regulation of the *Klrc* locus. Also, as noted in Figure 1, CD94 expression was equivalent to WT in the *Klrc1*<sup>-/-</sup> line. Because *Klrc2*, *Klrc3*, and *Klrd1* are the genes nearest to the targeted region, their unaltered expression indicates that the targeted deletion of *Klrc1* is specific and that the *Klrc1*<sup>-/-</sup> strain contains an otherwise intact *Klrc* locus.

To rule out the possibility that the targeted ES clone used to generate the mice contained other chromosomal mutations, particularly on the Y chromosome, that might be responsible for the ECTV phenotype, we bred male and female *Klrc1*<sup>-/-</sup> mice to C57BL/6 WT mice to generate heterozygotes; these were intercrossed to generate two groups of *Klrc1*<sup>-/-</sup>, *Klrc1*<sup>-/+</sup> and *Klrc1*<sup>+/+</sup> F2 mice, one with the Y chromosome from *Klrc1*<sup>-/-</sup> males and the

other with the Y chromosome from C57BL/6 males. The *Klrc1*<sup>-/-</sup> males from both groups of F2 mice were acutely susceptible to ECTV (Figures S2A-C), corroborating our initial observation that increased susceptibility to ECTV segregates with and is due to the targeted *Klrc1* mutation.

### **NKG2A deficiency results in fewer ECTV-specific CD8<sup>+</sup> T cells that exhibit increased effector functionality**

Given that mice die at 8-10 days after ECTV infection, and that NK cells and CD8<sup>+</sup> T cells predominate anti-ECTV responses at this stage (Parker et al., 2007) and express NKG2A, we evaluated the impact of NKG2A deficiency on CD8<sup>+</sup> T cell and NK cell responses. The number of *Klrc1*<sup>-/-</sup> specific CD8<sup>+</sup> T cells was markedly reduced after ECTV infection, as judged by B8R<sub>20-27</sub>-H2-K<sup>b</sup> tetramer staining, indicating that NKG2A may function to enhance the accumulation of specific CD8<sup>+</sup> T cells (Figure 3A). In contrast, *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cells restimulated *ex vivo* with the immunodominant epitope of the orthopoxvirus B8R protein (B8R<sub>20-27</sub>) had more intracellular IFN- $\gamma$  than did WT cells and expressed more CD107a, a marker of degranulation (Figure 3B). This indicates that, on a per cell basis, NKG2A inhibits effector functions of virus-specific CD8<sup>+</sup> T cells. In agreement, *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cells secreted greater quantities of IFN- $\gamma$  when stimulated with B8R<sub>20-27</sub> (Figure 3C). We also detected significantly higher quantities of IFN- $\gamma$  in the sera of *Klrc1*<sup>-/-</sup> males at 7 d.p.i. (Figure 3D). These data indicate that NKG2A may function to both limit CD8<sup>+</sup> T cell activation and sustain the specific CD8<sup>+</sup> T cell population in the context of ECTV infection.

Given the increased quantities of IFN- $\gamma$  found in *Klrc1*<sup>-/-</sup> mice, we next asked if NKG2A deficiency resulted in greater production of other cytokines by CD8<sup>+</sup> T cells. Notably, we found that higher amounts of granulocyte-monocyte colony stimulating factor (GM-CSF), but not tumor necrosis factor (TNF) or interleukin-2 (IL-2), was produced by virus-specific *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cells – the same T cells that produced high amounts of IFN- $\gamma$  (Figure 3E-G). As GM-CSF promotes myeloid cell accrual, this data suggests that during ECTV infection, NKG2A deficiency results specifically in polyfunctional IFN $\gamma$ <sup>hi</sup> GM-CSF<sup>+</sup> CD8<sup>+</sup> T cells that could contribute to the neutrophil and monocyte accumulation seen in *Klrc1*<sup>-/-</sup> spleens. Moreover, *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cells were generally larger and more granular than their WT counterparts at 7 d.p.i., but did not exhibit altered skewing toward a short-lived effector cell (SLEC) population or memory precursor effector cell (MPEC) (Figures 3H and 3I), suggesting that NKG2A limits general activation of ECTV-specific CD8<sup>+</sup> T cells.

### ***Klrc1*<sup>-/-</sup> NK cells remain functionally intact after ECTV infection**

We assessed NK cell function in the spleen at 5.5 d.p.i., when NKG2A expression on CD8<sup>+</sup> T cell control appears to be important for viral control. WT and *Klrc1*<sup>-/-</sup> NK cells restimulated *in vitro* with a tumor target cells expressed equivalent levels of both IFN- $\gamma$  and CD107a, indicating that NK cell function is largely maintained in the absence of NKG2A (Figure 3J). To determine whether *Klrc1*<sup>-/-</sup> NK cell function was altered at earlier time points, when CD8<sup>+</sup> T cells are not yet primed, we quantified the viral burden in draining popliteal lymph nodes 3 days after footpad infection with ECTV (Figure 3K). We chose this time point because early resistance to ECTV is more dependent on NK cells and popliteal

lymph nodes are the primary location for viral replication prior to systemic infection (Parker et al., 2007). However, there was no difference in viral burden in the popliteal lymph nodes at this time, suggesting that NKG2A plays an insignificant role in early NK cell-mediated control of ECTV infection. Thus, NKG2A expression on NK cells has no effect on the control of ECTV infection.

### ***Klrc1*<sup>-/-</sup> thymocytes develop normally and NKG2A marks a population of thymic NKT cells**

Given that NKG2A deficiency resulted in a reduced number of antiviral CD8<sup>+</sup> T cells, we sought to further assess the role of NKG2A in T cell development by analyzing thymuses of WT and *Klrc1*<sup>-/-</sup> mice. However, we found no differences in any thymocyte subset in *Klrc1*<sup>-/-</sup> mice (Figure S3A). We did observe that subsets of both CD4<sup>-</sup>CD8<sup>-</sup> and CD4 single-positive cells express NKG2A (Figure S3B). We found that these cells were thymic NKT cells, as judged by co-expression of NK1.1 and CD3 and the fact that NKG2A deficiency did not alter the accumulation of these cells in the thymus (Figure S3C). Together, these data show that NKG2A is not expressed on thymocytes and does not alter thymocyte development, but does mark a population of thymic NKT cells.

### ***Klrc1*<sup>-/-</sup> ECTV-specific CD8<sup>+</sup> T cells express genes associated with lymphocyte activation and apoptosis**

Given that NKG2A deficiency leads to excessive effector functions of CD8<sup>+</sup> T cells after ECTV infection, we sought to analyze whether NKG2A signaling altered specific transcriptional pathways associated with T cell activation. To test this, we sorted both naïve and ECTV-specific CD8<sup>+</sup> T cells and analyzed the transcriptomes *via* microarray analysis. WT and *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cell transcriptomes were broadly similar when assessed by principal component analysis (PCA) (Figure 4A). There were only mild variations in individual gene expression profiles of naïve CD8<sup>+</sup> T cells (Figure 4B). However, there were wider variations in the expression of 225 transcripts by ECTV-specific WT and *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cells (Figure 4C and 4D), which associated with specific pathways as judged by gene ontology pathway analysis (Figure 4E). *Klrc1*<sup>-/-</sup> cells contained an overabundance of transcripts falling within five categories of stimulatory pathways, including responses to stress and stimuli, cell proliferation, and lymphocyte activation. Several individual transcripts overabundant in *Klrc1*<sup>-/-</sup> cells were indicative of CD8<sup>+</sup> T cell activation, including *Ifng*, *Prfl*, *Rel*, *Batf3*, and *Bhlhe40* (Figure 4F). Upregulation of *Bhlhe40* most likely explains the augmented production of GM-CSF by virus-specific *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cells, as *Bhlhe40* positively regulates the production of GM-CSF (Lin et al., 2014). Importantly, *Klrc1*<sup>-/-</sup> cells also overexpressed *Bcl2l1l*, which encodes Bim, a key pro-apoptotic mediator. In contrast, WT ECTV-specific CD8<sup>+</sup> T cells featured an overabundance of transcripts that fell within immunoregulatory pathways, including *Il10*, *Il10r*, *Smad3*, and *Tnfrsf3* (Figure 4F). Differential expression of relevant genes was further verified by quantitative real-time PCR analysis of ECTV-specific CD8<sup>+</sup> T cell cDNA (Figure 4G). Overall, transcriptional changes in *Klrc1*<sup>-/-</sup> ECTV-specific CD8<sup>+</sup> T cells indicate that these cells are more activated than their WT counterparts and are potentially more susceptible to apoptosis.

### ***Klrc1*<sup>-/-</sup> specific CD8<sup>+</sup> T cells are intrinsically vulnerable to apoptosis**

Our previous data suggests that NKG2A limits effector functions of ECTV-specific CD8<sup>+</sup> T cells, while sustaining a higher number of specific CD8<sup>+</sup> T cells. This data, combined with the overabundance of *Bcl2l1l* transcript in *Klrc1*<sup>-/-</sup> specific CD8<sup>+</sup> T cells, led us to hypothesize that NKG2A has two distinct functions within CD8<sup>+</sup> T cells: to limit excessive effector function and to prevent unnecessary apoptosis. To test this *in vivo*, we designed an adoptive transfer system that would allow us to observe *Klrc1*<sup>-/-</sup> B8R-specific CD8<sup>+</sup> T cells in competition with WT B8R-specific CD8<sup>+</sup> T cells during ECTV infection (Figure 5A). To generate a pool of B8R-specific T cells, CD45.1 WT mice and CD45.2 *Klrc1*<sup>-/-</sup> mice were infected with an ova peptide-transgenic strain of ECTV (EV/NP-S-GFP) that causes less mortality in *Klrc1*<sup>-/-</sup> mice (Figure 5B). Approximately one week post-infection, splenic CD8<sup>+</sup> T cells from each strain were enriched and assessed for TCR specificity by staining with B8R-H2-K<sup>b</sup> tetramers, and then mixed at a 1:1 ratio of tetramer<sup>+</sup> cells (Figure 5C). This mixture was injected i.v. into *Rag1*<sup>-/-</sup> hosts, which were infected with WT-ECTV 1 day post-transfer. As a control, some *Rag1*<sup>-/-</sup> mice were given the T cell mixture, but not infected with virus. Uninfected *Rag1*<sup>-/-</sup> spleens did not harbor a significant population of specific T cells 8 days post-transfer. Hosts that were infected with WT virus, however, had a noticeable population of B8R-specific CD8<sup>+</sup> T cells (Figure 5D). In the infected hosts, WT (CD45.1) specific donor cells were more frequent and significantly outnumbered *Klrc1*<sup>-/-</sup> (CD45.2) donor cells (Figures 5E). This result establishes an *in vivo*, cell-intrinsic role for NKG2A on antigen-specific CD8<sup>+</sup> T cells in response to ECTV.

### **NKG2A-deficiency does not affect virus-specific CD8<sup>+</sup> T cells in a cell-extrinsic manner**

Although *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cells are intrinsically less stable than their WT counterparts after ECTV infection, it remained possible that T cell-extrinsic mechanisms, such as NK cell-mediated killing of DCs or T cells, might also contribute to the dysfunctional CD8<sup>+</sup> T cell response in *Klrc1*<sup>-/-</sup> mice. To determine whether any other NKG2A-expressing cell affects the CD8<sup>+</sup> T cell response *in vivo*, we designed another adoptive transfer experiment that would allow us to observe how donor WT B8R-specific CD8<sup>+</sup> T cells survived in either a WT or *Klrc1*<sup>-/-</sup> host environment following ECTV infection (Figure 5F). CD45.1 WT B8R-specific CD8<sup>+</sup> T cells survived equally well in both WT and *Klrc1*<sup>-/-</sup> CD45.2 hosts, as judged by the number of B8R-H2-K<sup>b</sup>CD45.1<sup>+</sup> donor cells present in host spleens 7 days post-infection with WT-ECTV (Figure 5G). Finally, several reports have indicated that NK cells are capable of killing virus-specific T cells or otherwise impeding their priming (Andrews et al., 2010; Crouse et al., 2014; Lu et al., 2007; Schuster et al., 2014; Waggoner et al., 2012; Waggoner et al., 2010; Xu et al., 2014). We therefore depleted NK cells prior to ECTV infection to assess if CD8<sup>+</sup> T cell numbers could be restored in the absence of NK cells. However, we found that antigen-specific CD8<sup>+</sup> T cells were highly reduced in both WT and *Klrc1*<sup>-/-</sup> spleens after NK cell depletion, indicating that NK cells likely function to control ECTV early enough to allow for the priming of an adequate CD8<sup>+</sup> T cell response (Figure 5H). Combined, this indicates that NKG2A expression on any cell other than the B8R-specific CD8<sup>+</sup> T cells appears to be unimportant for a functional specific T cell response.



### ***Klrc1*<sup>-/-</sup> ECTV-specific CD8<sup>+</sup> T cells are more susceptible to apoptosis**

To test whether the excessive apoptosis of ECTV-specific *Klrc1*<sup>-/-</sup> specific CD8<sup>+</sup> T cells was attributable directly to overactivation, we restimulated splenocytes from ECTV-infected mice *ex vivo* with increasing concentrations of plate-bound anti-CD3 antibody. After 2 days in culture with the plate-bound anti-CD3, we could not detect staining with the B8R-H2-K<sup>b</sup> tetramer, suggesting that the CD8<sup>+</sup> T cell population was highly activated to the point of TCR downregulation (data not shown). Total CD8<sup>+</sup> T cells of *Klrc1*<sup>-/-</sup> mice exhibited consistently higher Annexin V and 7AAD staining compared to WT controls and overall were more sensitive to apoptosis following CD3-induced activation (Figure 5I). In contrast, CD4<sup>+</sup> T cells from both strains were equally sensitive to CD3-induced apoptosis, indicating that enhanced susceptibility was limited to *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cells (Figure 5J). To determine whether *Klrc1*<sup>-/-</sup> ECTV-specific CD8<sup>+</sup> T cells were as susceptible to apoptosis as the total *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cell population, CD8<sup>+</sup> T cell viability and apoptosis was determined after *ex vivo* stimulation with low amounts of IL-2, which would not downregulate TCR expression. Antigen-specific CD8<sup>+</sup> T cell numbers and Annexin V binding were measured 1, 3, and 5 days after culture with IL-2. WT cell numbers increased *ex vivo*, whereas *Klrc1*<sup>-/-</sup> cell numbers decreased over the same time period (Figure 5K, left panel). The inverse was true of Annexin V staining; less than 5% of WT cells were Annexin V<sup>+</sup> by day 3, but approximately 25% of the remaining *Klrc1*<sup>-/-</sup> cells were beginning to undergo apoptosis (Figure 5K, right panel). This data indicates that NKG2A can function specifically within activated CD8<sup>+</sup> T cells to modulate activation and prevent aberrant apoptosis.

### **Qa-1 is preferentially expressed on B cells in ECTV-infected tissues**

Since NKG2A appears to function intrinsically within antigen-specific CD8<sup>+</sup> T cells, we reasoned that there must be an antigen-presenting cell (APC) population within an ECTV-infected secondary lymphoid tissue that expresses Qa-1 and can stimulate the CD8<sup>+</sup> T cell response. We found that naïve splenic B cells expressed low, but detectable, amounts of Qa-1 and that B cells in ECTV-infected spleens upregulate Qa-1 expression (Figure 6A). In both naïve and infected spleens, B cells expressed Qa-1 at higher amounts than non-B cells. Furthermore, when we infected WT and *Klrc1*<sup>-/-</sup> mice with the ova peptide-transgenic strain of ECTV used for the adoptive transfer immunizations, B cells in popliteal lymph nodes at 3 d.p.i. were activated and presented the ova peptide, as detected by a SIINFEKL-H2-K<sup>b</sup>-specific antibody. Thus, B cells are capable of both priming CD8<sup>+</sup> T cells and interacting with CD94/NKG2A heterodimers (Figure 6B). A similar observation was made in spleens at 7 d.p.i., with both WT and *Klrc1*<sup>-/-</sup> B cells presenting ECTV-derived antigen and undergoing activation (Figure 6C). Given the relative dominance of B cell numbers in the nodes and spleen, we hypothesize that B cells are the dominant APCs responsible for activating CD8<sup>+</sup> T cells and interacting with CD94/NKG2A heterodimers following ECTV infection.

### **NKG2A is dispensable for control of LCMV, VSV, and VV infections**

ECTV is somewhat unusual among mouse models of viral infection in that it is a natural pathogen that is acutely lethal in many murine strains at low infectious doses and hence requires robust innate and adaptive responses, even for subcutaneous infections of as little as

1000 PFU of virus. We were therefore interested in determining whether NKG2A is broadly necessary for combating viral infections and, furthermore, how different viruses would affect the CD8<sup>+</sup> T cell response in the absence of NKG2A. To do this, we chose to infect WT and *Klrc1*<sup>-/-</sup> mice with nonlethal viruses that cause either acute (VSV-ova) or chronic (LCMV clone 13) infection in C57BL/6 mice, as well as with VV, an attenuated orthopoxvirus that is highly homologous to ECTV. VSV-ova splenic viral loads were similar in *Klrc1*<sup>-/-</sup> and WT mice 8 hrs p.i. (Figure S4A). At 7 days p.i., after replicating virus was cleared from C57BL/6 mice, the specific CD8<sup>+</sup> T cell response in *Klrc1*<sup>-/-</sup> spleens was similar to WT controls, as judged by ova-H2-K<sup>b</sup>-tetramer staining (Figure S4B). Fifteen days after infection with LCMV clone 13, viral loads in spleen, liver, kidney, and lung were all equivalent in *Klrc1*<sup>-/-</sup> and WT C57BL/6 mice (Figure S4C). Following infection with VV, WT and *Klrc1*<sup>-/-</sup> mice lost little or no weight (Figure S4D), and had equivalent frequencies of specific and total CD8<sup>+</sup> T cells in spleens and draining lymph nodes (Figures S4E-F). Together, these data indicate that NKG2A may be necessary in antigen-activated T cells only during acute infections by highly replicative and cytopathic viruses, or perhaps specifically during ECTV infection.

## Discussion

In this study we have shown that *Klrc1*<sup>-/-</sup> mice are highly susceptible to infection by the mouse natural pathogen ECTV due to a defect in virus-specific CD8<sup>+</sup> T cell responses. This defect is cell intrinsic, as NKG2A expression is required to prevent excessive activation and AICD of virus-specific CD8<sup>+</sup> T cells. It is noteworthy that NKG2A is essential for host survival following ECTV infection, but is not required for responses to an attenuated poxvirus, VV, or other viruses tested in our study, including VSV and LCMV. This result suggests that evolution of the *Klrc* locus may have been driven by pressure imposed by deadly poxvirus infections that cause excessive stimulation of CD8<sup>+</sup> T cells.

One previous study found that CD94-deficient (*Klr1*<sup>-/-</sup>) mice are also highly susceptible to ECTV infection (Fang et al., 2011). However, susceptibility was associated with defective expression and function of NKG2E on NK cells. Our analysis of WT and *Klrc1*<sup>-/-</sup> mice revealed essentially no expression of NKG2C or NKG2E on NK cells, which is consistent with several other studies (Kawamura et al., 2009; Vance et al., 2002; Vance et al., 1999). Moreover, if undetected CD94/NKG2E heterodimers could mediate ECTV clearance, we would expect *Klrc1*<sup>-/-</sup> mice to be more resistant to ECTV infection than WT mice, because CD94/NKG2E-mediated activation would not be countered by NKG2A-mediated inhibition. Thus, susceptibility of *Klrd1*<sup>-/-</sup> mice to ECTV seems most likely due to lack of CD94/NKG2A heterodimers rather than lack of CD94/NKG2E heterodimers. However, because *Klrd1*<sup>-/-</sup> mice were generated on the 129 background and backcrossed onto C57BL/6 (Fang et al., 2011), it is also possible that the *Klrc* locus remained 129 in these mice and that the activating isoforms of NKG2X are expressed and functional in this background. Whatever the case, both studies highlight the importance of the *Klrc* locus in the control of acute poxvirus infections.

It is clear from our data that impaired CD8<sup>+</sup> T cell responses in ECTV-infected *Klrc1*<sup>-/-</sup> mice are due to a T cell-intrinsic rather than a T cell-extrinsic defect. Why does lack of

NKG2A have a dramatic effect during acute ECTV infection but no impact on VV, LCMV and VSV infections? NKG2A-mediated inhibition may be essential during anti-ECTV responses because ECTV is a natural pathogen that is highly replicative and may provoke extreme antigenic stimulation of CD8<sup>+</sup> T cells. ECTV is also highly cytopathic and aggressively infects secondary lymphoid tissues, such as the spleen and popliteal lymph nodes, disrupting their architecture (Esteban and Buller, 2005). This could attenuate initial T cell priming and further stress the relatively few virus-specific T cells that need to control infection in a highly inflammatory environment. In this scenario, the lack of NKG2A, which restrains overactivation, may have catastrophic effects.

It is also possible that during non-ECTV infections other inhibitory receptor-ligand interactions contribute more than NKG2A to finely tune CD8<sup>+</sup> T cell activation. This has been demonstrated during chronic LCMV infection, in which the absence of the inhibitory receptor 2B4 results in a suboptimal T cell response and exacerbated chronic disease (Waggoner et al., 2010). Although it was recently shown that T cells express Qa-1 during chronic LCMV infection, perhaps protecting them from NK cell-mediated lysis by engaging CD94/NKG2A heterodimers (Xu et al., 2014), in our study, lack of NKG2A did not impact the course of chronic LCMV infection. NKG2A was also dispensable for sustaining specific CD8<sup>+</sup> T cells during influenza virus and adenovirus infections, but did limit immunopathology (Ely et al., 2014). Thus, we postulate that NKG2A may have various effects during different viral infections. These effects range from preventing extreme activation and AICD (ECTV infection); limiting effector responses and immunopathology (influenza and adenovirus); no detectable impact due to the contribution of other inhibitory interactions (LCMV); and perhaps exhaustion and reduced control of viral replication (chronic infections yet to be identified).

During ECTV infection, all cells expressing Qa-1 can deliver an inhibitory signal to NKG2A<sup>+</sup>CD8<sup>+</sup> T cells that prevents AICD. However, we noticed that B cells express Qa-1 at higher amounts than non-B cells in both naïve and infected spleens. Furthermore, we demonstrated that B cells are infected by ECTV and present viral peptides, which has been corroborated by a recent study (Sei et al., 2015). Thus, B cells may be the dominant APCs that activate CD8<sup>+</sup> T cells and interact with CD94/NKG2A heterodimers during ECTV infection. Upon engagement, CD94/NKG2A heterodimers most likely optimize CD8<sup>+</sup> T cell activation through recruitment of SHP-1 and inhibition of tyrosine kinases, thereby preventing AICD. A similar mechanism was previously proposed for the ability of the human inhibitory receptor KIR2DL3 to attenuate AICD of memory CD8<sup>+</sup> T cells in response to peptide stimulation *in vitro* (Ugolini et al., 2001). Additionally, since the TCR co-receptor CD8 can bind to Qa-1, CD94/NKG2A heterodimers may be crucial for outcompeting CD8 binding and limiting CD8-mediated costimulation after initial T cell priming.

This study reshapes our understanding of surface expression of the *Klrc* locus-encoded receptors in mice. We demonstrate that mouse NKG2C and NKG2E are not expressed on the cell surface, at least in the B6 background. CD94 is mainly associated with NKG2A in CD94<sup>high</sup> NK cells and CD94<sup>high</sup> activated CD8<sup>+</sup> T cells. However, CD94 remains expressed on CD94<sup>low</sup> NK cells in the absence of NKG2X as part of a complex with

DAP12. Since activated CD8<sup>+</sup> T cells express DAP10 but not DAP12 it is likely CD94 pairs with DAP10 in activated CD8<sup>+</sup> T cells that lack NKG2X, although this conclusion should be conclusively confirmed through the generation of *Klrc1*<sup>-/-</sup> × *Hcst*<sup>-/-</sup> mice. These results are in agreement with a previous demonstration that mouse CD94 directly associates with DAP12 and DAP10 through a salt bridge in the transmembrane region without requiring NKG2C or NKG2E (Saether et al., 2011). Further studies will be essential to define the function of CD94/DAP12 and CD94/DAP10 complexes.

## Experimental Procedures

### Mice

*Klrc1*<sup>-/-</sup> (Figure S1), WT C57BL/6J, *Hcst*<sup>-/-</sup> and B6.*Rag1*<sup>-/-</sup> mice were housed in specific pathogen-free conditions at Washington University in St. Louis and St. Louis University. B6.SJL-Ptprca Pepcb/BoyJ mice (CD45.1<sup>+</sup> C57BL/6 strain) were purchased from Jackson Laboratory and subsequently bred in-house. *Tyrbp*<sup>-/-</sup> mice were originated by Toshiyuki Takai (Tohoku University, Japan).

### Viruses and viral infections

Plaque-purified ECTV (Moscow strain) was propagated on BS-C-1 cells. EV/NP-S-GFP contains a FluNP-SIINFEKL-GFP cassette in the disrupted V region (CrmC) of ECTV-Moscow (Parker et al., 2007). All ECTV and EV/NP-S-GFP infections were done in the f.p. at the indicated doses. ECTV viremia was assessed by quantitative real-time PCR of the EV107 gene. 5×10<sup>6</sup> PFU Indiana strain VSV-ova was injected intravenously (i.v.). LCMV clone 13 was administered i.v. at 2×10<sup>6</sup> PFU per mouse. Mice were infected in the f.p. with 1.25×10<sup>7</sup> PFU vaccinia SIINFEKL GFP virus (virus was provided by Dr. John Yewdell, NIAID). Viral loads were assessed from various tissues by standard plaque assays on BS-C-1 (for ECTV) or Vero (for VSV-ova, LCMV clone 13) cell monolayers.

### Flow cytometry

Antibodies, reagents, and staining methods can be found in the Supplemental Information. All samples were run on either a BD FACS Calibur or BD FACS Canto II system and analyzed with FlowJo software (Tree Star, Inc.).

### T cell restimulation assay

Splenocytes from ECTV-infected mice were incubated overnight at 37°C in complete RPMI with either irrelevant peptide (SIINFEKL) or the poxvirus immunodominant peptide B8R (TSYKFESV). Supernatants were collected and IFN-γ concentration was measured with the Mouse Inflammation CBA kit (BD Biosciences). GM-CSF concentration was measured with Mouse GM-CSF ELISA Ready-SET-Go! (eBioscience). For intracellular detection of cytokines, cells were incubated for 6 hours in the presence of peptide and both brefeldin A (BD Biosciences) and monensin (eBioscience), then stained as described in the Supplemental Information.

## RNA isolation, microarray and real-time PCR analysis

Cells were directly sorted into Buffer RLT Plus and RNA was isolated using the RNeasy Plus Micro kit (Qiagen). All RNA samples were then processed and hybridized to Mouse Gene 1.0 ST arrays (Affymetrix) by Washington University's Genome Technology Access Center. Detailed information on microarray procedures and analysis can be found in the Supplemental Information. cDNA was synthesized using a SuperScript first-strand synthesis system (Invitrogen). Real-time quantitative PCR reactions were setup with iQ SYBR Green Supermix (Bio-Rad) and specific primers (see Supplemental Information) and run on a Bio-Rad iCycler.

## T cell apoptosis assay

Splenocytes from ECTV-infected mice were put into 96-well plates ( $2 \times 10^6$  cells/well) with complete RPMI supplemented with 13ng/ml recombinant human IL-2 (Peprotech). 1, 3, and 5 days later, cells were stained with Annexin V and 7-AAD (PE Annexin V Apoptosis Detection Kit, BD Pharmingen). B8R-H2-K<sup>b</sup>-APC tetramers and anti-CD8-FITC antibody were added to the staining cocktail to mark specific CD8<sup>+</sup> T cells. Cells were then analyzed by flow cytometry. In some experiments, splenocytes from ECTV-infected mice were cultured on plates coated with or without purified anti-CD3 $\epsilon$ . After 2 days, cells were analyzed for the same apoptosis markers on either total CD8<sup>+</sup> or CD4<sup>+</sup> T cells.

## Statistics

A Student's t test or multiple t tests were performed in Prism (GraphPad) in all cases. Mean  $\pm$  SEM is represented on relevant graphs. \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.001$ ; \*\*\*\* $p < 0.0001$ .

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgements


M.C was supported by the NIH grant 1R56AI119083-01, A.S.R. by the NIH training grant T32-AI007172, B.P. by the Rheumatic Diseases Core Center grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (P30-AR048335) and W.M.Y. by the Howard Hughes Medical Institute. The authors thank the NIH Tetramer Core Facility (contract HHSN272201300006C) for provision of MHC tetramers, Scott Parker for technical assistance, John Yewdell for vaccinia virus and Christina Song for help with preparing this manuscript.

## REFERENCES

- Aldrich CJ, DeCloux A, Woods AS, Cotter RJ, Soloski MJ, Forman J. Identification of a Tap-dependent leader peptide recognized by alloreactive T cells specific for a class Ib antigen. *Cell*. 1994; 79:649–658. [PubMed: 7525079]
- Andrews DM, Estcourt MJ, Andoniou CE, Wikstrom ME, Khong A, Voigt V, Fleming P, Tabarias H, Hill GR, van der Most RG, et al. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. *J. Exp. Med.* 2010; 207:1333–1343. [PubMed: 20513749]
- Biron CA. Expansion, maintenance, and memory in NK and T cells during viral infections: responding to pressures for defense and regulation. *PLoS Pathog.* 2010; 6:e1000816. [PubMed: 20361055]


- Braud VM, Allan DS, O'Callaghan CA, Soderstrom K, D'Andrea A, Ogg GS, Lazetic S, Young NT, Bell JI, Phillips JH, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. *Nature*. 1998; 391:795–799. [PubMed: 9486650]
- Brownstein DG, Gras L. Chromosome mapping of Rmp-4, a gonad-dependent gene encoding host resistance to mousepox. *J. Virol.* 1995; 69:6958–6964. [PubMed: 7474114]
- Call ME, Wucherpennig KW, Chou JJ. The structural basis for intramembrane assembly of an activating immunoreceptor complex. *Nat. Immunol.* 2010; 11:1023–1029. [PubMed: 20890284]
- Crouse J, Bedenikovic G, Wiesel M, Ibberson M, Xenarios I, Von Laer D, Kalinke U, Vivier E, Jonjic S, Oxenius A. Type I Interferons Protect T Cells against NK Cell Attack Mediated by the Activating Receptor NCR1. *Immunity*. 2014; 40:961–973. [PubMed: 24909889]
- Ely KH, Matsuoka M, DeBerge MP, Ruby JA, Liu J, Schneider MJ, Wang Y, Hahn YS, Enelow RI. Tissue-protective effects of NKG2A in immune-mediated clearance of virus infection. *PLoS One*. 2014; 9:e108385. [PubMed: 25251060]
- Esteban DJ, Buller RM. Ectromelia virus: the causative agent of mousepox. *J. Gen. Virol.* 2005; 86:2645–2659. [PubMed: 16186218]
- Fang M, Orr MT, Spee P, Egebjerg T, Lanier LL, Sigal LJ. CD94 is essential for NK cell-mediated resistance to a lethal viral disease. *Immunity*. 2011; 34:579–589. [PubMed: 21439856]
- Frebel H, Nindl V, Schuepbach RA, Braunschweiler T, Richter K, Vogel J, Wagner CA, Loffing-Cueni D, Kurrer M, Ludewig B, Oxenius A. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. *J. Exp. Med.* 2012; 209:2485–2499. [PubMed: 23230000]
- Gunturi A, Berg RE, Forman J. Preferential survival of CD8 T and NK cells expressing high levels of CD94. *J. Immunol.* 2003; 170:1737–1745. [PubMed: 12574337]
- Kabat J, Borrego F, Brooks A, Coligan JE. Role that each NKG2A immunoreceptor tyrosine-based inhibitory motif plays in mediating the human CD94/NKG2A inhibitory signal. *J. Immunol.* 2002; 169:1948–1958. [PubMed: 12165520]
- Kawamura T, Takeda K, Kaneda H, Matsumoto H, Hayakawa Y, Raulet DH, Ikarashi Y, Kronenberg M, Yagita H, Kinoshita K, et al. NKG2A inhibits invariant NKT cell activation in hepatic injury. *J. Immunol.* 2009; 182:250–258. [PubMed: 19109156]
- Lanier LL. Evolutionary struggles between NK cells and viruses. *Nat. Rev. Immunol.* 2008; 8:259–268. [PubMed: 18340344]
- Le Drean E, Vely F, Olcese L, Cambiaggi A, Guia S, Krystal G, Gervois N, Moretta A, Jotereau F, Vivier E. Inhibition of antigen-induced T cell response and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. *Eur. J. Immunol.* 1998; 28:264–276. [PubMed: 9485206]
- Lee N, Llano M, Carretero M, Ishitani A, Navarro F, Lopez-Botet M, Geraghty DE. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. *Proc. Natl. Acad. Sci. USA.* 1998; 95:5199–5204. [PubMed: 9560253]
- Lin CC, Bradstreet TR, Schwarzkopf EA, Sim J, Carrero JA, Chou C, Cook LE, Egawa T, Taneja R, Murphy TL, et al. Bhlhe40 controls cytokine production by T cells and is essential for pathogenicity in autoimmune neuroinflammation. *Nat. Commun.* 2014; 5:3551. [PubMed: 24699451]
- Lu L, Ikizawa K, Hu D, Werneck MB, Wucherpennig KW, Cantor H. Regulation of activated CD4+ T cells by NK cells via the Qa-1-NKG2A inhibitory pathway. *Immunity*. 2007; 26:593–604. [PubMed: 17509909]
- McMahon CW, Zajac AJ, Jamieson AM, Corral L, Hammer GE, Ahmed R, Raulet DH. Viral and bacterial infections induce expression of multiple NK cell receptors in responding CD8(+) T cells. *J. Immunol.* 2002; 169:1444–1452. [PubMed: 12133970]
- Miller JD, Peters M, Oran AE, Beresford GW, Harrington L, Boss JM, Altman JD. CD94/NKG2 expression does not inhibit cytotoxic function of lymphocytic choriomeningitis virus-specific CD8+ T cells. *J. Immunol.* 2002; 169:693–701. [PubMed: 12097371]
- Moser JM, Gibbs J, Jensen PE, Lukacher AE. CD94-NKG2A receptors regulate antiviral CD8(+) T cell responses. *Nat. Immunol.* 2002; 3:189–195. [PubMed: 11812997]

- Odorizzi PM, Wherry EJ. Inhibitory receptors on lymphocytes: insights from infections. *J. Immunol.* 2012; 188:2957–2965. [PubMed: 22442493]
- Parker AK, Parker S, Yokoyama WM, Corbett JA, Buller RM. Induction of natural killer cell responses by ectromelia virus controls infection. *J. Virol.* 2007; 81:4070–4079. [PubMed: 17287257]
- Rygiel TP, Rijkers ES, de Ruiter T, Stolte EH, van der Valk M, Rimmelzwaan GF, Boon L, van Loon AM, Coenjaerts FE, Hoek RM, et al. Lack of CD200 enhances pathological T cell responses during influenza infection. *J. Immunol.* 2009; 183:1990–1996. [PubMed: 19587022]
- Saether PC, Hoelsbrekken SE, Fossum S, Dissen E. Rat and mouse CD94 associate directly with the activating transmembrane adaptor proteins DAP12 and DAP10 and activate NK cell cytotoxicity. *J. Immunol.* 2011; 187:6365–6373. [PubMed: 22084441]
- Schuster IS, Wikstrom ME, Brizard G, Coudert JD, Estcourt MJ, Manzur M, O'Reilly LA, Smyth MJ, Trapani JA, Hill GR, et al. TRAIL+ NK cells control CD4+ T cell responses during chronic viral infection to limit autoimmunity. *Immunity.* 2014; 41:646–656. [PubMed: 25367576]
- Sei JJ, Haskett S, Kaminsky LW, Lin E, Truckenmiller ME, Bellone CJ, Buller RM, Norbury CC. Peptide-MHC-I from Endogenous Antigen Outnumber Those from Exogenous Antigen, Irrespective of APC Phenotype or Activation. *PLoS Pathog.* 2015; 11:e1004941. [PubMed: 26107264]
- Sullivan LC, Clements CS, Beddoe T, Johnson D, Hoare HL, Lin J, Huyton T, Hopkins EJ, Reid HH, Wilce MC, et al. The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition. *Immunity.* 2007; 27:900–911. [PubMed: 18083576]
- Taylor LS, Paul SP, McVicar DW. Paired inhibitory and activating receptor signals. *Rev. Immunogenet.* 2000; 2:204–219. [PubMed: 11258418]
- Tomasec P, Braud VM, Rickards C, Powell MB, McSharry BP, Gadola S, Cerundolo V, Borysiewicz LK, McMichael AJ, Wilkinson GW. Surface expression of HLA-E, an inhibitor of natural killer cells, enhanced by human cytomegalovirus gpUL40. *Science.* 2000; 287:1031. [PubMed: 10669413]
- Ugolini S, Arpin C, Anfossi N, Walzer T, Cambiaggi A, Forster R, Lipp M, Toes RE, Melief CJ, Marvel J, Vivier E. Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells. *Nat. Immunol.* 2001; 2:430–435. [PubMed: 11323697]
- Vance RE, Jamieson AM, Cado D, Raulet DH. Implications of CD94 deficiency and monoallelic NKG2A expression for natural killer cell development and repertoire formation. *Proc. Natl. Acad. Sci. USA.* 2002; 99:868–873. [PubMed: 11782535]
- Vance RE, Jamieson AM, Raulet DH. Recognition of the class Ib molecule Qa-1(b) by putative activating receptors CD94/NKG2C and CD94/NKG2E on mouse natural killer cells. *J. Exp. Med.* 1999; 190:1801–1812. [PubMed: 10601355]
- Vance RE, Kraft JR, Altman JD, Jensen PE, Raulet DH. Mouse CD94/NKG2A is a natural killer cell receptor for the nonclassical major histocompatibility complex (MHC) class I molecule Qa-1(b). *J. Exp. Med.* 1998; 188:1841–1848. [PubMed: 9815261]
- Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. *Nature.* 2012; 481:394–398. [PubMed: 22101430]
- Waggoner SN, Taniguchi RT, Mathew PA, Kumar V, Welsh RM. Absence of mouse 2B4 promotes NK cell-mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis. *J. Clin. Invest.* 2010; 120:1925–1938. [PubMed: 20440077]
- Xu HC, Grusdat M, Pandya AA, Polz R, Huang J, Sharma P, Deenen R, Kohrer K, Rahbar R, Diefenbach A, et al. Type I interferon protects antiviral CD8(+) T cells from NK cell cytotoxicity. *Immunity.* 2014; 40:949–960. [PubMed: 24909887]
- Zeng L, Sullivan LC, Vivian JP, Walpole NG, Harpur CM, Rossjohn J, Clements CS, Brooks AG. A structural basis for antigen presentation by the MHC class Ib molecule, Qa-1b. *J. Immunol.* 2012; 188:302–310. [PubMed: 22131332]




**Figure 1. NK and CD8<sup>+</sup> T cells do not express NKG2C or NKG2E on the cell surface**  
**(A, B)** Splensens were analyzed by flow cytometry for surface expression of NKG2ACE and CD94 under naïve conditions or 7 days post-infection (d.p.i.) of footpads (f.p) with 1000 PFU ECTV-Moscow. NK cells (A) and CD8<sup>+</sup> T cells (B) are depicted. **(C)** CD94 expression was measured on splenic NK cells (top panel) and CD8<sup>+</sup> T cells (bottom panel). Both histograms depict naïve WT cells (black dashed line), naïve *Klrc1*<sup>-/-</sup> cells (red dashed line), ECTV-stimulated WT cells (black solid line), ECTV-stimulated *Klrc1*<sup>-/-</sup> cells (red solid line). Cells stained with an isotype control antibodies fell within black bars. **(D)** Naïve splenic NK cells from WT, *Hcst*<sup>-/-</sup> and *Tyrobp*<sup>-/-</sup> mice were assessed for CD94<sup>low</sup> and CD94<sup>high</sup> populations. **(E)** Ly49H, NKG2ACE, and CD94 were assessed on WT and *Tyrobp*<sup>-/-</sup> naïve splenic NK cells. **(F)** NKG2ACE and CD94 expression was measured on total CD8<sup>+</sup> T cells from WT and *Hcst*<sup>-/-</sup> mice. Mice were infected with LCMV clone 13 and on day 8 p.i., splensens were isolated. **(G)** Schematic of NKG2A and CD94 surface expression on mouse killer cells. Data is representative of at least 3 independent experiments. Further supporting evidence can be found in Supplemental Figure 1 and Supplemental Table 1.





**Figure 2. *Klrc1*<sup>-/-</sup> mice are more susceptible to ECTV infection**

WT and *Klrc1*<sup>-/-</sup> mice were infected with ECTV and monitored for survival (A) and body weight (B) over time. (C) Viral load was assessed at 6 d.p.i. ECTV genome load in the blood was measured by quantitative RT-PCR. Spleen and liver viral loads were determined by plaque assay. Black bars indicate WT tissues and white bars indicate *Klrc1*<sup>-/-</sup> tissues. (D) WT (black circles) and *Klrc1*<sup>-/-</sup> (white circles) blood was collected from ECTV-infected animals 6 d.p.i. and was assessed by complete white blood cell (WBC) counts and WBC differentials (segmented neutrophil, lymphocyte, and platelet counts). (E, F) WT (E) and *Klrc1*<sup>-/-</sup> (F) spleens were fixed and stained with H&E 6 d.p.i. Original magnification 40×. Scale bar=20µm. (G) Total splenocyte and splenic leukocyte cell numbers were assessed 7 d.p.i. (H) Neutrophils (CD11b<sup>+</sup>Ly6C<sup>+</sup>Ly6G<sup>+</sup>) and monocytes (CD11b<sup>+</sup>Ly6C<sup>+</sup>Ly6G<sup>-</sup>) frequencies and cell numbers were assessed 7 d.p.i. Panels E and F are representative of 2 independent experiments. All other data were pooled from at least 2 independent experiments and were analyzed by multiple t tests. Further supporting evidence can be found in Supplemental Figure 2 and Supplemental Table 1.



**Figure 3. Characterization of WT and *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cell and NK cell responses to ECTV**  
 Mice were infected with ECTV and spleens analyzed for CD8<sup>+</sup> T cell responses 7 d.p.i. (A) CD3<sup>+</sup>CD8<sup>+</sup>BBR-H2-K<sup>b</sup> T cell numbers were quantified from spleens. (B) WT or *Klrc1*<sup>-/-</sup> splenocytes were pulsed *ex vivo* with irrelevant SIINFEKL peptide or poxvirus-specific B8R<sub>20-27</sub>, then assessed for CD107a and IFN- $\gamma$  expression by intracellular staining of CD3<sup>+</sup>CD8<sup>+</sup> lymphocytes. The frequency of CD107a<sup>+</sup>IFN- $\gamma$ <sup>+</sup> CD8<sup>+</sup> T cells and MFI of IFN- $\gamma$ <sup>+</sup> cells were quantified from WT (black bars) and *Klrc1*<sup>-/-</sup> splenocytes (white bars). (C) Splenocytes were incubated overnight with irrelevant or B8R<sub>20-27</sub> peptides to restimulate CD8<sup>+</sup> T cells. IFN- $\gamma$  accumulation in the supernatant was quantified by bead array. (D) IFN- $\gamma$  concentration was measured from the sera of ECTV-infected mice by bead array. (E) Splenocytes were treated as in panel A, then assessed for GM-CSF intracellular content. GM-CSF<sup>+</sup> cell frequency and MFI of GM-CSF<sup>+</sup> cells are shown. (F) Splenocytes were treated as in panel C. GM-CSF accumulation in the supernatant was quantified by ELISA. (G) Splenocytes were treated as in panel A, and TNF or IL-2 intracellular content was determined. (H) CD3<sup>+</sup>CD8<sup>+</sup> lymphocyte blasting was assessed by FSC and SSC. (I) Total CD3<sup>+</sup>CD8<sup>+</sup> lymphocytes were analyzed for KLRG1 and CD127 expression. Frequency of


SLEC (KLRG1<sup>+</sup>CD127<sup>-</sup>) and MPEC (KLRG1<sup>-</sup>CD127<sup>+</sup>) populations are shown. **(J)** Expression of IFN- $\gamma$  and CD107a in splenic NK cells were measured 5.5 d.p.i. Splenocytes were incubated with or without  $1 \times 10^5$  YAC-1 targets cells, then stained for NK cell markers and intracellular IFN- $\gamma$ . Dot plots show CD107a and IFN- $\gamma$  expression on CD3<sup>-</sup>NK1.1<sup>+</sup> NK cells. **(K)** Viral load in popliteal lymph nodes was assessed by plaque assay 3 days p.i. All data are pooled from at least 2 independent experiments and were analyzed by multiple t tests. Further supporting evidence can be found in Supplemental Figure 3.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript



**Figure 4. Differential expression of genes associated with lymphocyte activation in *Klrc1*<sup>-/-</sup> ECTV-specific CD8<sup>+</sup> T cells**  
 CD3<sup>+</sup>CD8<sup>+</sup>B8R-H2-K<sup>b+</sup> T cells were sorted from WT and *Klrc1*<sup>-/-</sup> mice infected with ECTV and total RNA was isolated. As a control, RNA was isolated from total CD3<sup>+</sup>CD8<sup>+</sup> T cells of naïve WT and *Klrc1*<sup>-/-</sup> mice. Transcriptomes of all RNA samples were assessed by microarray analysis. (A) Principal component analysis of total naïve and ECTV-specific CD8<sup>+</sup> T cells. Naïve WT (blue dots), naïve *Klrc1*<sup>-/-</sup> (green dots), WT infected (purple dots), and *Klrc1*<sup>-/-</sup> infected (orange dots) samples are shown. (B, C) Volcano plots of naïve WT versus naïve *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cells (B) or ECTV-specific WT versus ECTV-specific *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cells (C). Transcripts differentially expressed in *Klrc1*<sup>-/-</sup> cells (blue dots) versus WT cells (red dots) are labeled. *Klrc1* is also indicated in both plots. (D) Heatmap of all genes differentially expressed between WT and *Klrc1*<sup>-/-</sup> CD8<sup>+</sup> T cells. The scale ranges from minimum (green boxes) to medium (black boxes) to maximum (red boxes) relative


expression. **(E)** Gene ontology pathway analysis of ECTV-specific CD8<sup>+</sup> T cells. Red bars indicate pathways overrepresented in WT cells and blue bars indicate pathways overrepresented in *Klrc1*<sup>-/-</sup> cells. **(F)** Heatmap of genes representative of the differentially expressed pathways depicted in (E). Coloration is equivalent to that used in (D). **(G)** Quantitative RT-PCR amplification of relevant genes to validate microarray analysis data. All transcripts are shown relative to *Gapdh* copy number.

Author Manuscript

Author Manuscript


Author Manuscript

Author Manuscript



**Figure 5. NKG2A limits apoptosis of virus-specific CD8<sup>+</sup> T cells in a cell-intrinsic manner**  
 (A) Schematic to test for a cell-intrinsic mechanism of NKG2A function in ECTV-specific CD8<sup>+</sup> T cell survival. (B) WT and *Klrc1*<sup>-/-</sup> male mice were infected f.p. with either 7000PFU ECTV-WT or 9000PFU EV/NP-S-GFP and survival was monitored for 7.5 weeks post-infection. (C) WT<sup>CD45.1</sup> and *Klrc1*<sup>-/-</sup> mice were immunized with 5000PFU ECTV-ova f.p. and CD8<sup>+</sup> T cells were enriched from spleens 7 d.p.i. via MACS selection. Cells were then mixed at a 1:1 ratio of B8R-H2-K<sup>b</sup> cells and adoptively transferred into *Rag1*<sup>-/-</sup> hosts. (D) *Rag1*<sup>-/-</sup> hosts were either left uninfected or were infected with ECTV-WT for 7

days, then analyzed for B8R-H2-K<sup>b+</sup> CD8<sup>+</sup> T cells. **(E)** Frequencies of WT and *Klrc1*<sup>-/-</sup> CD3<sup>+</sup>CD8<sup>+</sup>B8R-H2-K<sup>b+</sup> cells from *Rag1*<sup>-/-</sup> spleens 7 d.p.i. with ECTV-WT. Total CD3<sup>+</sup>CD8<sup>+</sup>B8R-H2-K<sup>b+</sup> cell numbers from naïve or ECTV-WT-infected *Rag1*<sup>-/-</sup> spleens are shown on the right. **(F)** Schematic to test for a cell-extrinsic mechanism of NKG2A function in ECTV-specific CD8<sup>+</sup> T cells. **(G)** Total number of specific donor cells (CD45.1<sup>+</sup>CD3<sup>+</sup>CD8<sup>+</sup>B8R-H2-K<sup>b+</sup> cells) isolated from naïve hosts or ECTV-WT-infected hosts. **(H)** Mice were treated with either control or NK cell-depleting antibody prior to infection with 200 PFU ECTV-WT. On days 6 or 8 post-infection, spleens were isolated and antigen-specific CD8<sup>+</sup> T cell numbers were quantified. **(I)** WT and *Klrc1*<sup>-/-</sup> splenocytes were isolated 7 days after ECTV infection and put in culture in the presence or absence of plate-bound anti-CD3 antibody. After 2 days, CD8<sup>+</sup> T cells were assessed for Annexin V (left panel) and 7AAD (right panel). **(J)** Cells were prepared as in panel I and CD4<sup>+</sup> T cells were analyzed. **(K)** WT and *Klrc1*<sup>-/-</sup> splenocytes were isolated 7 days after ECTV infection and cultured in complete RPMI containing 13ng/ml rhIL-2. At 1, 3, and 5 days post-culture, numbers of CD8<sup>+</sup>B8R-H2-K<sup>b+</sup> cells were quantified (left panel) and assessed for Annexin V staining (right panel). All panels depict WT cells (filled circles/bars) and *Klrc1*<sup>-/-</sup> cells (open circles/bars). All data are representative of at least 2 independent experiments and were analyzed by multiple t tests.



**Figure 6. Qa-1 is preferentially expressed on ECTV-activated B cells**

(A) Splenocytes from naïve or ECTV-infected mice were assessed for Qa-1 expression. Qa-1 MFI of CD19<sup>+</sup> versus CD19<sup>-</sup> splenocytes is shown on the left. Expression of Qa-1 on splenic B cells from naïve or ECTV-infected mice is shown on the right. (B) CD19<sup>+</sup> popliteal lymph nodes B cells were assessed for H2-K<sup>b</sup>-SIINFEKL and CD86 expression with specific antibodies 3 days after infection with EV/NP-S-GFP. (C) CD19<sup>+</sup> splenic B cells were assessed H2-K<sup>b</sup>-SIINFEKL and CD86 expression 7 days after infection with EV/NP-S-GFP or from uninfected naïve B cells. Data is representative of at least 3



independent experiments. Further supporting evidence can be found in Supplemental Figure 4.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript